Key Takeaways Catalyst Pharmaceuticals' Q3 EPS of $0.68 beat estimates on 15% year-over-year revenue growth.Firdapse sales rose 16%, while Agamree revenues more than doubled amid strong product demand.CPRX lifted 2025 revenue guidance to $565M-$585M following strong Q3 earnings results.Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the third quarter of 2025, beating the Zacks Consensus Estimate of 51 cents. The company had recorded adjusted earnings of 57 cents in the y ...